ArticleFrontiers in microbiology2020
Molecular Characterization of Fecal Extended-Spectrum β-Lactamase- and AmpC β-Lactamase-Producing
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Poultry-associated nitrofurantoin-resistant and pre-resistantOne health (Amsterdam, Netherlands) · 2025Article
- Extended Spectrum Beta-Lactamase Producing Escherichia coli in Pet Cats and Dogs in Central Peninsular Malaysia.Veterinary medicine and science · 2025Article
- Antimicrobial Resistance Patterns of ESBL-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Whole genome sequencing analysis of enteropathogenicJournal of veterinary science · 2025Article
- Comprehensive regional study of ESBLFrontiers in microbiology · 2025Article
- Evolution of extended-spectrum β-lactamase-producing ST131 Escherichia coli at a single hospital over 15 years.Scientific reports · 2024Article
- Multidrug-resistant phenotypes of genetically diverse Escherichia coli isolates from healthy domestic cats.Scientific reports · 2024Article
- Comparison of IncK-Antibiotics (Basel, Switzerland) · 2024Article
- Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2023Article
- Evolution of extended-spectrum β-lactamase-producing ST131bioRxiv : the preprint server for biology · 2023Article
- Article
- Prevalence and Characterization of Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Comparative genetic characterization of CMY-2-type beta-lactamase producing pathogenic Escherichia coli isolated from humans and pigs suffering from diarrhea in Korea.Annals of clinical microbiology and antimicrobials · 2023Article
- Genetic Diversity and New Sequence Types ofGenes · 2022Article
- Multidrug-Resistant High-RiskAntibiotics (Basel, Switzerland) · 2022Article
- Companion Animals as Potential Reservoirs of Antibiotic Resistant DiarrheagenicAntibiotics (Basel, Switzerland) · 2022Article
- Evidence that faecal carriage of resistantOne health (Amsterdam, Netherlands) · 2022Article
- The Bacterial Urban Resistome: Recent Advances.Antibiotics (Basel, Switzerland) · 2022Review
- Global prevalence and molecular characterization of extended-spectrum β-lactamase producing-One health (Amsterdam, Netherlands) · 2021Article
- Whole-genome analyses of extended-spectrum or AmpC β-lactamase-producing Escherichia coli isolates from companion dogs in Japan.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to describe the distribution and characterization of fecal extended-spectrum β-lactamase (ESBL)- and AmpC-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.